Showing results (51-60 of 187) with videos related to

Sort By:
Pageof 19
The American Naturalist|March 9, 2018
The Condition-Dependent Development of Carotenoid-Based and Structural Plumage in Nestling Blue Tits: Males and Females DifferAnne Peters, Kaspar Delhey, Arild Johnsen, et al.
Annals of Medicine|August 15, 2018
Approaches to rapid acting insulin intensification in patients with type 2 diabetes mellitus not achieving glycemic targetsAlexandra Migdal, Martin Abrahamson, Anne Peters, et al.
Plos One|July 21, 2010
Seasonal changes in colour: a comparison of structural, melanin- and carotenoid-based plumage coloursKaspar Delhey, Claudia Burger, Wolfgang Fiedler, et al.
Plos One|February 26, 2013
Male songbird indicates body size with low-pitched advertising songsMichelle L Hall, Sjouke A Kingma, Anne Peters
Frontiers in Clinical Diabetes and Healthcare|June 11, 2026
Feasibility and preliminary outcomes of a peer-led diabetes self-management support program for black men: the michigan men's diabetes project (MenD II)Jaclynn M Hawkins, Alana M Ewen, Maricruz Moya, et al.
Diabetes Care|August 19, 2007
Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulinMatthew Riddle, Juan Frias, Bei Zhang, et al.
Diabetes/Metabolism Research and Reviews|September 27, 2014
Patterns of postprandial hyperglycemia after basal insulin therapy: individual and regional differencesCharles Shaefer, Timothy Reid, Andres DiGenio, et al.
Patient Education and Counseling|June 8, 2015
Interplay among patient empowerment and clinical and person-centered outcomes in type 2 diabetes. The BENCH-D studyMaria Chiara Rossi, Giuseppe Lucisano, Martha Funnell, et al.
Molecular Ecology Resources|August 15, 2017
Increasing the accuracy and precision of relative telomere length estimates by RT qPCRJustin R Eastwood, Ellis Mulder, Simon Verhulst, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|February 17, 2022
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health systemCarlos Balmaceda, Manuel A Espinoza, Tomas Abbott, et al.
Pageof 19